Chief Scientific Officer · Nurix Therapeutics, Inc. · Common Stock
Side
SELL
Value
$80K
Shares
4,797
Price
$16.58
Executed
Jan 30, 2026
Disclosed
Jan 30, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jan 30 executedJan 30, 2026 disclosed
NRIX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Hansen Gwenn filed this Form 4 reporting a open-market sale of NRIX on Jan 30, 2026. It became public on Jan 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Scientific Officer
Hansen Gwenncik:0001817160
Issuer
Nurix Therapeutics, Inc.cik:0001549595
Revision history · 0
No field has changed since this record was first ingested.
